Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH plus ) Chronic Myeloid Leukemia (CML) or PH plus Acute Lymphoblastic Leukemia (ALL): a Pharmacokinetic Study

被引：0
|
作者：
Hijiya, Nobuko [1 ]
Zwaan, C. Michel [1 ]
Rizzari, Carmelo [1 ]
Foa, Roberto [1 ]
Abbink, Floor [1 ]
Lancaster, Donna [1 ]
Landman-Parker, Judith [1 ]
Millot, Frederic [1 ]
Moppett, John [1 ]
Nelken, Brigitte [1 ]
Ducassou, Stephane [1 ]
Putti, Maria Caterina [1 ]
Tian, Xianbin [1 ]
Sinclair, Karen [1 ]
Santanastasio, Helene [1 ]
Buchbinder, Aby [1 ]
Kearns, Pamela [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [41] Therapy Optimization and Challenges in MRD-positive or recurrent Philadelphia Chromosome-positive acute Lymphocytic Leukemia (Ph plus ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (11) : 614 - 615
  • [42] Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph plus ALL)
    Kyo, Taiichi
    Okatani, Takeshi
    Kyo, Kouhei
    Imanaka, Ryouta
    Itagaki, Mitsuhiro
    Katayama, Yuuta
    Iwato, Koji
    Asaoku, Hideki
    BLOOD, 2011, 118 (21) : 652 - 652
  • [43] Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase (Ph plus CML early CP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Rios, MB
    Shan, J
    Hayes, K
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [44] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
    Jabbour, Elias
    Martinelli, Giovanni
    Vignetti, Marco
    Kantarjian, Hagop
    Gomez-Almaguer, David
    Minami, Yosuke
    Dombret, Herve
    Hennessy, Meliessa
    Vorog, Alexander
    Wang, Bingxia
    Ribera, Josep-Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
  • [45] Maxizyme, a novel ribozyme, induces cell death of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph plus ALL).
    Soda, Y
    Tani, K
    Bai, YS
    Chen, MH
    Izawa, K
    Saiki, M
    Kuwabara, T
    Warashina, M
    Tanabe, T
    Miyoshi, H
    Sugita, K
    Nakazawa, S
    Tojo, A
    Taira, K
    Asano, S
    BLOOD, 2002, 100 (11) : 656A - 656A
  • [46] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Short, Nicholas
    Daver, Naval
    Pemmaraju, Naveen
    Thomas, Deborah
    Yilmaz, Musa
    Kadia, Tapan
    Sasaki, Koji
    Garris, Rebecca
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Weirda, William
    Jeanis, Vicky
    Cortes, Jorge
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258
  • [47] A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph plus ) Acute Myeloid Leukemia (AML)
    Senapati, Jayastu
    Ravandi, Farhad
    DiNardo, Courtney D.
    Issa, Ghayas C.
    Sasaki, Koji
    Konopleva, Marina
    Pemmaraju, Naveen
    Chien, Kelly S.
    Ohanian, Maro
    Jabbour, Elias
    Maiti, Abhishek
    Roy, Edith
    Delumpa, Ricardo
    Rivera, Juan
    Loiselle, Christopher
    Banks, Glenda
    Kantarjian, Hagop
    Short, Nicholas
    BLOOD, 2022, 140 : 3880 - 3882
  • [48] Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
    Samra, Bachar
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Khouri, Rita
    Khoury, Joseph D.
    Champlin, Richard E.
    Kebriaei, Partow
    Cortes, Jorge E.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Borthakur, Gautam M.
    Verstovsek, Srdan
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Jain, Nitin
    Konopleva, Marina Y.
    Yilmaz, Musa E.
    Naqvi, Kiran
    O'Brien, Susan M.
    Ravandi, Farhad
    Jabbour, Elias
    BLOOD, 2019, 134
  • [49] Philadelphia chromosome-positive Acute Lymphoblastic Leukemia
    Forghieri, Fabio
    Luppi, Mario
    Potenza, Leonardo
    HEMATOLOGY, 2015, 20 (10) : 618 - 619
  • [50] Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph plus CML-CP) with and without the T315I Mutation
    Combes, Francois Pierre
    Li, Ying Fei
    Sy, Sherwin K. B.
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    BLOOD, 2022, 140 : 6791 - 6792
12345